明德生物 (002932)

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

ASZ

Tags

DeepSeekSpecialized-Sophisticated-Distinctive-Innovative EnterprisesCSI Dividend IndexLow Price-to-Book RatioVenture Capital ConceptMedical DevicesGuoxin Value IndexGene ConceptNon-GAAP LossesEmerging Markets IndexSmart HealthcareBelow Net Asset ValueAssisted ReproductionRestructuring ProposalsHigh Price-to-Earnings RatioHigh-Dividend Yield StocksSZSE Medicine Equal Weight IndexShenzhen A-Share Pharmaceutical IndexHubei IndexCSI All-share Pharmaceutical Sector IndexEmerging Technology 100 IndexSZSE 700 IndexSSE 700 Growth IndexSHS Technology 100 IndexSZSE 1000 IndexCSI 1000 Growth IndexSHS High Dividend Yield IndexCSWD Life Sciences IndexExcellent Performance Strategy IndexSZSE Performance IndexGrowth 40 IndexNew Virus PreventionCOVID-19 PreventionAugust 2022 Lock-up ExpiryAntigen Self-testCOVID-19 TestingPrivate PlacementInsurance Heavy HoldingsStocks Below Book ValueSME Board Composite IndexPublic Health IndexSZSE Selected IndexCNI 2000 IndexSME Board Innovation IndexEmerging Industries Composite IndexManufacturing IndexCS Pharmaceutical TI IndexCSI 1000 IndexCS Pharmaceutical Innovation IndexSME Board Dividend IndexPharmaceutical 50 IndexCSI Life Sciences IndexDividend 200 IndexChina Economic Index GDPCSI 1000 Value IndexCSI 1000 Value Stable IndexPerformance Index

K-Line Chart

No K-line data available

Company NameWuhan MINDRAY Bio-medical Electronics Co., Ltd.
Listing Date2018-07-10
Issue Price20.45RMB
Registered Capital23252.095710k RMB
Legal RepresentativeChen Lili
Registered AddressArea C, Unit 1, Floor 1, Building 1, Wuhan MINDRAY Bio-medical Electronics Industrial Park (Phase I) (All for Self-use), No. 77 Jiulong Middle Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province.
IndustryMedical Devices
Main BusinessIndependent R&D, production, and sales of POCT rapid diagnostic reagents and rapid testing instruments.
Company ProfileThe company's predecessor, Wuhan MINDRAY Bio-medical Electronics Co., Ltd., was established on January 28, 2008, funded by natural persons Wang Ying, Chen Lili, Zu Shuhua, Chen Yonggen, and Wang Hanying. On September 30, 2013, the company held an extraordinary shareholders' meeting and unanimously agreed to convert the limited company into a joint-stock company. On October 23, 2013, the joint-stock company (in preparation) held its founding meeting and first shareholders' meeting, and obtained the 'Business License' issued by the Donghu High-tech Development Zone Branch of the Wuhan Administration for Industry and Commerce on November 13, 2013, officially establishing Wuhan MINDRAY Bio-medical Electronics Co., Ltd.

Stock Details

1. Key Indicators

  • Total Shares(W): 23252.10
  • Circulating A-Shares(W): 15608.52
  • Earnings Per Share(RMB): 0.0616
  • Net Assets Per Share(RMB): 23.9167
  • Operating Revenue(W RMB): 22680.82
  • Total Profit(W RMB): -527.80
  • Net Profit Attributable to Parent(W RMB): 1351.55
  • Net Profit Growth Rate(%): -83.30
  • Weighted Return on Equity(%): 0.2400
  • Operating Cash Flow Per Share(RMB): -0.3800
  • Undistributed Profit Per Share(RMB): 17.7522
  • Capital Reserve Per Share(RMB): 3.5184

2. Main Business

The main business covers:

  • Research, development, production, sales and service of in vitro diagnostic reagents and diagnostic instruments

3. Company Basic Information

  • Company Name: Wuhan Easy Diagnosis Biomedicine Co., Ltd.
  • Listing Date: 2018-07-10
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 77 Jiulong Middle Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province
  • Website: www.mdeasydiagnosis.com
  • Company Profile: The company was established by the overall change of Mingde Co., Ltd. into a joint stock company. Based on the audited net assets of 9,646,112.83 yuan as of August 31, 2013, Mingde Co., Ltd. was converted into 6 million shares at a ratio of 1.6077:1 and transformed into a joint stock company. On November 13, 2013, the company obtained the "Business License of Enterprise Legal Person" with registration number 420100000053229 from the Wuhan Administration for Industry and Commerce.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 GF Value Core Hybrid Securities Investment Fund A Class Fund 284.62 1.82
2 Rongtong China Wind No.1 Flexible Allocation Hybrid Securities Investment Fund A Class Fund 230.06 1.47
3 E Fund CSI Dividend Tradable Open-End Index Securities Investment Fund Fund 228.09 1.46
4 Rongtong Health Industry Flexible Allocation Hybrid Securities Investment Fund A Class Fund 220.06 1.41
5 China Merchants CSI Dividend Tradable Open-End Index Securities Investment Fund Fund 189.63 1.21
6 Xinyuan Specialized, Sophisticated, Distinctive and New Enterprise Selection Theme Hybrid Securities Investment Fund A Class Fund 35.37 0.23

5. Concept Sectors

  • Venture Capital Concept
  • Gene Concept
  • Intelligent Healthcare
  • Assisted Reproduction
  • Hepatitis Concept
  • DeepSeek
  • Margin Trading
  • Low Price-to-Book Ratio
  • High Price-to-Earnings Ratio
  • Below Net Asset Value
  • High Dividend Stocks
  • Non-Recurring Loss
  • Restructuring Plan
  • Specialized, Sophisticated, Distinctive and New
  • Yesterday's Strong Performer
  • Yesterday's Sudden Surge

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information